Expression of 5α-reductase in apocrine carcinoma of the breast and its correlation with clinicopathological aggressiveness

Histopathology

Volumn 60, Issue 6 B, 2012, Pages

  Kasashima, Satomi ^a   Kawashima, Atsuhiro ^a   Ozaki, Satoru ^b   Nakanuma, Yasuni ^b  

^a NATIONAL HOSPITAL ORGANIZATION KANAZAWA MEDICAL CENTER   (Japan)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Androgen; Autocrine synthesis; Breast apocrine carcinoma; Invasion; Sex steroid producing enzyme

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53; STEROID 5ALPHA REDUCTASE;

ADULT; AGED; APOCRINE CARCINOMA; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CARCINOMA, DUCTAL, BREAST; CHOLESTENONE 5 ALPHA-REDUCTASE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED;

EID: 84860349434     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04214.x     Document Type: Article

References (28)

1. Frable WJ, Kay S. Carcinoma of the breast. Histologic and clinical features of apocrine tumors. Cancer 1968; 21; 756-763.
2. Abati AD, Kimmel M, Rosen PP. Apocrine mammary carcinoma. A clinicopathologic study of 72 cases. Am. J. Clin. Pathol. 1990; 94; 371-377.
3. Tavassoli FA, Purcell CA, Bratthauer GL, Man Y. Androgen receptor expression along with loss of bcl-2, ER, and PR expression in benign and malignant apocrine lesions of the breast: implications for therapy. Breast J. 1996; 2; 261-269.
4. Honma N, Sakamoto G, Akiyama F et al. Breast carcinoma in women over the age of 85: distinct histological pattern and androgen, oestrogen, and progesterone receptor status. Histopathology 2003; 42; 120-127.
5. Celis JE, Cabezón T, Moreira JM et al. Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort. Mol. Oncol. 2009; 3; 220-237.
6. Vranic S, Tawfik O, Palazzo J et al. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod. Pathol. 2010; 23; 644-653.
7. Thigpen AE, Silver RI, Guileyardo JM et al. Tissue distribution and ontogeny of steroid 5α-reducatse isozome expression. J. Clin. Invest. 1993; 92; 903-910.
8. Russell DW, Wilson JD. Steroid 5a-reductase: two genes/two enzymes. Annu. Rev. Biochem. 1994; 63; 25-61.
9. Suzuki T, Miki Y, Takagi K et al. Androgens in human breast carcinoma. Med. Mol. Morphol. 2010; 43; 75-81.
10. Wako K, Kawasaki T, Yamana K et al. Expression of androgen receptor through androgen-converting enzyme is associated with biological aggressiveness in prostate cancer. J. Clin. Pathol. 2008; 61; 448-454.
11. Kasashima S, Ozaki S, Kawashima A, Zen Y, Moriya T, Inoue M. Androgen receptor and 5alpha-reductase immunohistochemical profiles in extramammary Paget disease. Br. J. Dermatol. 2010; 162; 1098-1102.
12. Park S, Koo J, Park HS et al. Expression of androgen receptors in primary breast cancer. Ann. Oncol. 2010; 21; 488-492.
13. Gonzalez LO, Corte MD, Vazquez J et al. Androgen receptor expression in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer 2008; 28; 149.
14. Gonzalez LO, Junquera S, del Casar JM et al. Immunohistochemical study of matrix metalloproteinases and their inhibitors in pure and mixed invasive and in situ ductal carcinomas of the breast. Hum. Pathol. 2010; 41; 980-989.
15. Doane AS, Danso M, Lal P et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006; 29; 3994-4008.
16. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007; 1; 109.
17. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19; 403-410.
18. Moinfar F, Okcu M, Tsybrovskyy O et al. Androgen receptors frequently are expressed in breast carcinomas. Cancer 2003; 98; 703-711.
19. Honma N, Takubo K, Akiyama F et al. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. Histopathology 2005; 47; 195-201.
20. Tanaka K, Imoto S, Wada N, Sakemura N, Hasebe K. Invasive apocrine carcinoma of the breast: clinicopathologic features of 57 patients. Breast J. 2008; 14; 164-168.
21. Birrell SN, Roder DM, Horsfall DJ, Bentel JM, Tilley WD. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. J. Clin. Oncol. 1995; 13; 1572-1577.
22. Moe RE, Anderson BO. Androgens and androgen receptors: a clinically neglected sector in breast cancer biology. J. Surg. Oncol. 2007; 95; 437-439.
23. Mostaghel EA, Geng L, Holcomb I et al. Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention. Cancer Res. 2010; 15; 1286-1295.
24. Gonzalez LO, Corte MD, Junquera S, Bongera M, Rodriguez JC, Vizoso FJ. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast. Histopathology 2007; 50; 866-874.
25. Pang ST, Flores-Morales A, Skoog L, Chuan YC, Nordstedt G, Pousette A. Regulation of matrix metalloproteinase 13 expression by androgen in prostate cancer. Oncol. Rep. 2004; 11; 1187-1192.
26. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000; 21; 427-433.
27. Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer? Breast Cancer 2008; 15; 303-308.
28. Han JS, Cao D, Molberg KH et al. Hormone receptor status rather than HER2 status is significantly associated with increased Ki-67 and p53 expression in triple-negative breast carcinomas, and high expression of Ki-67 but not p53 is significantly associated with axillary nodal metastasis in triple-negative and high-grade non-triple-negative breast carcinomas. Am. J. Clin. Pathol. 2011; 135; 230-237.